BNET Industries
Market Cap:$38.5M
Last Fiscal Year Sales:$5.0M
- Public
- US
Dow Jones Description
Biological Products
Chairman, President & CEO
Steven R. ArikianNumber of Employees 60
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
News & Analysis
Filter by
biovest international inc. and fda - All News and Analysis
Accentia Biopharmaceuticals Reports Fiscal Second Quarter Financial Results
- 2008-05-16
Company to Present at Jefferies Healthcare Conference TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that the Company has filed its Quarterly Report (Form 10-Q) with the SEC, reporting the results of its operations, including consolidated results with its majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), for its second...
Accentia Biopharmaceuticals Receives NASDAQ Compliance Notice
- 2008-04-18
TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that it received notice from The NASDAQ Stock Market dated April 15, 2008, notifying the Company that it is not in compliance with NASDAQ Rule 4450b(1)A, which requires a listed security to maintain a minimum $50 million market capitalization for continued...
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
- 2008-03-24
TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that its Phase 3 clinical trial evaluating the Company's exclusively-licensed technology from the Mayo Clinic consisting of an intranasal antifungal lavage, SinuNase[TM] (topical amphotericin B 0.01% suspension) achieved, as anticipated, superior resolution of the cardinal symptoms of chronic sinusitis CS, as...
Accentia Receives Official Designation as a Certified National Community Development Entity from the United States Treasury Department
- 2007-10-08
Designation Enables Company to Seek Suballocations of Grants from Established CDE's and to Make Direct Application for Grants from the Annual $3.5 Billion New Market Tax Credit NMTC Program at the U.S. Treasury to Facilitate Financings of Biotechnology Products and Companies Accentia Pioneered the use of NMTCs to Support...
Interim Analysis of Anti-Cancer Vaccine, BiovaxID, to be Conducted
- 2007-06-13
Independent Data Monitoring Committee Requests Data Lock and Report of Interim Analysis BiovaxID Phase 3 Clinical Trial Has No Identifiable Safety Concerns WORCESTER, Mass. -- Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announces a milestone in its effort to gain accelerated...
Accentia Biopharmaceuticals' Majority-Owned Subsidiary, Biovest, Receives Request From the Independent Data Monitoring Committee to Conduct Interim Analysis of Anti-Cancer Vaccine, BiovaxID
- 2007-06-13
Independent Data Monitoring Committee Requests Data Lock and Report of Interim Analysis BiovaxID Phase 3 Clinical Trial Has No Identifiable Safety Concerns TAMPA, Fla. -- Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announces a milestone in its effort to gain accelerated...
Investor Update.
- 2007-06-12
M2 PRESSWIRE-12 June 2007-Businessnetwire.us: Investor UpdateC1994-2007 M2 COMMUNICATIONS LTD RDATE:12062007 New York, NY -- BusinessNetWire's "Investor's Update" Focuses on the Following Companies: COMMERCE PLANET, INC. (OTCBB: CPNE); BIOVEST INTERNATIONAL, INC. (OTCBB: BVTI); ODYNE CORPORATION (OTCBB: ODYC); CYBERKINETICS ...
Biovest and VWR Enter Into Marketing and Distribution Agreement for AutovaxID
- 2007-06-12
Dedicated AutovaxID Manufacturing Facility in St. Louis to be Operational September 2007 WORCESTER, Mass. -- Biovest International, Inc. (OTCBB:BVTI) a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) has entered into a distribution agreement with VWR International, Inc., to distribute its breakthrough AutovaxID[TM] automated cell culture device in...
Accentia Biopharmaceuticals' Majority-Owned Subsidiary, Biovest, and VWR International, Inc. Enter Into Marketing and Distribution Agreement for AutovaxID
- 2007-06-12
Dedicated AutovaxID Manufacturing Facility in St. Louis to be Operational September 2007 TAMPA, Fla. -- Biovest International, Inc. (OTCBB:BVTI) a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) has entered into a distribution agreement with VWR International, Inc., to distribute its breakthrough AutovaxID[TM] automated cell culture device in...
NIAID Supports Research Into Etiology of Fungal-Induced Inflammation in Chronic Sinusitis
- 2007-06-01
Grant Supports Identification of Fungal Antigens Responsible for Chronic Sinusitis Which May Also Play a Role in Asthma Accentia Biopharmaceuticals is the Exclusive Licensee to an Intranasal Antifungal for Treatment of Chronic Sinusitis TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI; Accentia) reports that the Mayo Medical and...
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Carl Cohen | COO |
| James A. McNulty | CFO & Secretary |
| Jim Wachholz | Chief Regulatory Officer |
| Julian Casciano | Chief Marketing Officer |
| Mark D. Hirschel | Chief Scientific Officer |
| Sam Duffey | General Counsel |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Steven R. Arikian | Chairman, President & CEO |
| Christopher Chapman | Board of Directors |
| Francis E. O'Donnell | Vice Chairman |
| Jeffery Scott | Board of Directors |
| John Sitilides | Board of Directors |
| Martin G. Baum | Board of Directors |
| Nick Leb | Board of Directors |
| Peter J. Pappas | Board of Directors |
| Raphael Mannino | Board of Directors |
| Robert D. Weiss | Board of Directors |
| Stephane E. Allard | Board of Directors |
Steven R. Arikian, M.D. began serving as a director in April 2002. Since November 2004, Dr. Arikian has served as President and Chief Operating Officer of Product Development and Market Services. In February 2005, his title was changed to President and Chief Operating Officer, Biopharmaceutical Products and Services. From January 2003 to November 2004, he was President of Pre-Market Services and Operations and from April 2002 to January 2003, he was President of Pre-Market Services. Since 1997, Dr. Arikian has served as the Chairman, Chief Executive Officer, and founder of our Analytica subsidiary, and September 2004, he has served and the Chairman and Chief Executive Officer of Biovest. Since 2003, Dr. Arikian has served as a director, and since 2004 has served as Chief Executive Officer, President, and Chairman, of Biovest International, Inc., our majority-owned, publicly held subsidiary. Dr. Arikian began providing pharmaceutical clients with Clinical and Outcomes Research services in 1988. He served as President of The Center for Health Outcomes and Economics at Bristol Myers Squibb from May 1995 to July 1997, where he supervised a staff of over 50 professionals responsible for development of global health outcomes research. He has designed and implemented research projects in the United States, Canada, Latin America and Europe. Dr. Arikian holds a faculty appointment at the Columbia University Mailman School of Public Health. He has also held faculty appointments at the University of Toronto and the University of Kentucky. He is widely published in the peer-reviewed literature and has been a frequent speaker at industry and trade group sponsored meetings on topics including Formulary Management, Pharmaceutical Pricing, Multi-National Health Economic Studies, and Pharmacoepidemiology. Dr. Arikian is a graduate of Fordham University with a degree in Biology and is also a graduate of the University of Catania (Italy) Medical School.
| Organization | Position | Status |
|---|---|---|
| Accentia BioPharmaceuticals, Inc. | Chairman, CEO | Current |
| BioVest International Inc. | Chairman, President & CEO | Current |
| Biovest International, Inc. | Chairman and CEO | Current |
| Analytica Group Limited | President | Current |
| Market Services | President | Current |
| Market Services | Chief Operating Officer | Current |
| Product Development Corporation | Chief Operating Officer | Current |
| Analytica Group Limited | Founder | Current |
| Analytica International, Inc. | Director | Current |
| Analytica Group Limited | Director | Current |
| Biovest International, Inc. | President | Former |
| Product Development Corporation | President | Former |
| Bristol-Myers Squibb Company | President | Former |
| Co-Operations Inc | President | Former |
| Analytica International, Inc. | Founder | Former |
| University of Toronto | Faculty | Former |
| University of Kentucky | Faculty | Former |
| Fordham University | Degree In Biology | Former |
| Accentia BioPharmaceuticals, Inc. | Director | Former |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | COO | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | CFO & Secretary | Current |
| BioVest International Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Chief Regulatory Officer | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Chief Marketing Officer | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Chief Scientific Officer | Current |
Samuel S. Duffey, Esq. has served as a director and our General Counsel since April 2003. Prior to that, Mr. Duffey practiced business law with Duffey and Dolan P.A. beginning in 1992. From February 2000, to September 2003, Mr. Duffey served as the non-executive chairman and as a member of the board of directors of Invisia, Inc., a small publicly held safety company, and from October 2001 to May 2004, Mr. Duffey also served as the non-executive chairman and as a member of the board of directors of FlashPoint International, Inc., a publicly held automotive parts company which is currently named Navitrak International Corporation. Mr. Duffey received his B.A. and J.D. degrees from Drake University.
| Organization | Position | Status |
|---|---|---|
| Accentia BioPharmaceuticals, Inc. | President & General Counsel | Current |
| The Hopkins Capital Group | General Legal Counsel | Current |
| Biovest International, Inc. | General Legal Counsel | Current |
| BioVest International Inc. | General Counsel | Current |
| Biovest International, Inc. | Board of Directors | Current |
| Accentia BioPharmaceuticals, Inc. | Director | Current |
| BioVest International Inc. | Board of Directors | Current |
| Navitrak International Corporation | Former | |
| Drake University | J.D. Degrees | Former |
| Drake University Law School | Juri Doctor Degree with honors | Former |
| Drake University | B.A. | Former |
| Drake University | Degree With Honors | Former |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Vice Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Board of Directors | Current |
Martin G. Baum began serving as one of our directors and as our President and Chief Operating Officer of Commercial Operations and Business Development in June 2003. In February 2005, his title was changed to President and Chief Operating Officer, Specialty Pharmaceuticals. He has also served as Chairman, President and Chief Executive Officer of our TEAMM subsidiary since its founding in July 2000. Prior to that, Mr. Baum served as Senior Vice President of Commercial Operations at DJ Pharmaceuticals, Inc., a specialty pharmaceutical company, since January 1999. Since June 2003, Mr. Baum has also been a director of Biovest International, Inc., our majority owned, publicly held subsidiary. Mr. Baum is a graduate of The University of Toledo, where he received B.S. degrees in Pre-Med and Business.
| Organization | Position | Status |
|---|---|---|
| Biovest International, Inc. | Director | Current |
| Accentia BioPharmaceuticals, Inc. | Board of Directors | Current |
| BioVest International Inc. | Board of Directors | Current |
| SkyePharma PLC | Former | |
| Analytica International, Inc. | Former | |
| Biovail Corporation | Former | |
| University of Toledo | Former |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| BioVest International Inc. | Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
